aflibercept vs ranibizumab
Side-by-side comparison of aflibercept and ranibizumab Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Eylea
Lucentis
AHZANTIVE is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.
CIMERLI is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.
AHZANTIVE treats wet age-related macular degeneration (AMD). It also treats swelling in the macula (the central part of the retina) caused by retinal vein occlusion (RVO) or diabetic macular edema (DME). Additionally, it can treat diabetic retinopathy (DR), an eye disease caused by diabetes.
CIMERLI treats several eye conditions. These include wet age-related macular degeneration (AMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV). These conditions can cause blurry vision or vision loss. CIMERLI helps to improve or stabilize your vision.
AHZANTIVE is a VEGF inhibitor. VEGF is a protein that promotes the growth of new blood vessels. By blocking VEGF, AHZANTIVE helps to reduce the growth of abnormal blood vessels in the eye and decrease leakage.
CIMERLI blocks a protein called vascular endothelial growth factor (VEGF). VEGF can cause abnormal blood vessels to grow in the eye. By blocking VEGF, CIMERLI helps to reduce blood vessel growth and leakage.
- • Bleeding in the eye
- • Eye pain
- • Clouding of the lens of the eye (cataract)
- • Separation of the vitreous gel from the retina
- • Spots in your vision
- • Redness in the eye
- • Eye pain
- • Seeing spots or floaters
- • Increased pressure in the eye
- • Clouding of the lens in the eye
- Death 7,853
- Trouble seeing 2,013
- Using the medicine for something it's not approved for 1,509
- Loss of sight 1,459
- Eye infection 1,372
- Death 3,784
- Worse vision 2,889
- Using the drug for something it's not approved for 1,676
- Vision problems 1,624
- Stroke 1,235
Injections with AHZANTIVE may cause serious eye infections (endophthalmitis), separation of the retina (retinal detachment), and inflammation of blood vessels in the retina. Tell your doctor right away if you have any signs of these problems. AHZANTIVE may also increase the risk of blood clots that can cause stroke or heart attack.
Injections with CIMERLI may cause an eye infection or a detached retina. Tell your doctor right away if you have eye pain, redness, or changes in vision. CIMERLI may increase the risk of blood clots, stroke, or heart attack. There have been rare cases of death in patients with diabetes who were treated with CIMERLI.
It is not known if AHZANTIVE can harm an unborn baby. AHZANTIVE should be used during pregnancy only if the benefit justifies the risk. It is also not known if AHZANTIVE passes into breast milk.
It is not known if CIMERLI can harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. It is not known if CIMERLI passes into breast milk. Talk to your doctor about the risks and benefits of breastfeeding while using CIMERLI.
How to Read This aflibercept vs ranibizumab Comparison
aflibercept is classified in the Anti-VEGF (Ophthalmic Injection) drug class, while ranibizumab sits within the Anti-VEGF (Ophthalmic Injection) class. Because both drugs share the same classification, they are often considered interchangeable in theory — but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aflibercept has 14,206 submissions while ranibizumab has 11,208. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aflibercept and ranibizumab — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.